{"filing":{"accession_number":"0001213900-26-075233","cik":"0001660046","ticker":"IMRN","company_name":"Immuron Ltd","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"ea0297074-6k_immuron.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1660046/000121390026075233/ea0297074-6k_immuron.htm"},"events":[{"id":16125,"run_id":14388,"accession_number":"0001213900-26-075233","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Immuron announced engagement of Pullan Consulting to advance partnering strategy for IMM-529, a clinical-stage CDI therapeutic with FDA IND approval. The disclosure details the company's strategic initiative to secure a development and commercialization partner, including market opportunity assessment (projected $400M base case annual revenue) and historical CDI deal benchmarks. This is a material operational/strategic milestone advancing a key asset toward commercialization, but does not fit discrete event categories like M\u0026A (no deal executed), exec changes, or financial events—it is a business development initiative that would affect investor assessment of the company's strategy and value creation path.","company_name":"Immuron Ltd","ticker":"IMRN","filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":[{"id":14121,"accession_number":"0001213900-26-075233","item_number":"EX-99.1","item_title":"ea029707401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Immuron announced engagement of Pullan Consulting to advance partnering strategy for IMM-529, a clinical-stage CDI therapeutic with FDA IND approval. The disclosure details the company's strategic initiative to secure a development and commercialization partner, including market opportunity assessment (projected $400M base case annual revenue) and historical CDI deal benchmarks. This is a material operational/strategic milestone advancing a key asset toward commercialization, but does not fit discrete event categories like M\u0026A (no deal executed), exec changes, or financial events—it is a business development initiative that would affect investor assessment of the company's strategy and value creation path.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:04:01.669396+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14121,"accession_number":"0001213900-26-075233","item_number":"EX-99.1","item_title":"ea029707401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Immuron announced engagement of Pullan Consulting to advance partnering strategy for IMM-529, a clinical-stage CDI therapeutic with FDA IND approval. The disclosure details the company's strategic initiative to secure a development and commercialization partner, including market opportunity assessment (projected $400M base case annual revenue) and historical CDI deal benchmarks. This is a material operational/strategic milestone advancing a key asset toward commercialization, but does not fit discrete event categories like M\u0026A (no deal executed), exec changes, or financial events—it is a business development initiative that would affect investor assessment of the company's strategy and value creation path.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-06T12:04:01.669396+00:00","company_name":"Immuron Ltd","ticker":"IMRN","filing_date":"2026-07-06"}]}